HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of a high cardiovascular risk patient with McArdle's disease with PCSK9 inhibitors.

Abstract
A 60-year-old male with familial combined hyperlipidemia, ischemic heart disease and type 2 diabetes. Since childhood, intolerance to intense exercise. The patient was diagnosed of McArdle's disease after an episode of rhabdomyolysis associated with statins as treatment after a myocardial infarction. Since then, he had been treated with diet, fibrates and ezetimibe with good tolerance, despite this, LDL cholesterol (cLDL) remained >180mg/dl. He started to be treated with alirocumab 150mg/sc every 14 days, with excellent clinical response and a decrease in cLDL to 15mg/dl. Our case shows that PCSK9 inhibitors are effective and safe in patients with muscle diseases who have statin contraindication, and they are a good therapeutic tool for these patients.
AuthorsVictoria Marco-Benedí, Estíbaliz Jarauta, Sofía Pérez-Calahorra, Ana M Bea, Fernando Civeira
JournalClinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis (Clin Investig Arterioscler) 2019 Mar - Apr Vol. 31 Issue 2 Pg. 89-92 ISSN: 1578-1879 [Electronic] Spain
Vernacular TitleTratamiento de un varón con enfermedad de McArdle y muy alto riesgo cardiovascular con inhibidores de PCSK9.
PMID30738610 (Publication Type: Case Reports, Journal Article)
CopyrightCopyright © 2018 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved.
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Anticholesteremic Agents
  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • PCSK9 Inhibitors
  • PCSK9 protein, human
  • alirocumab
Topics
  • Antibodies, Monoclonal (adverse effects, therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Anticholesteremic Agents (adverse effects, pharmacology, therapeutic use)
  • Cardiovascular Diseases (etiology, prevention & control)
  • Cholesterol, LDL (blood)
  • Glycogen Storage Disease Type V (etiology)
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors (administration & dosage, adverse effects)
  • Hyperlipidemia, Familial Combined (drug therapy)
  • Male
  • Middle Aged
  • Myocardial Infarction (drug therapy)
  • PCSK9 Inhibitors
  • Rhabdomyolysis (chemically induced, complications)
  • Risk Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: